RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

by | PRNewswire Asia

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years,...

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

by | PRNewswire Asia

TOKYO, Dec. 8, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as...

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

by | PRNewswire Asia

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support...

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

by | PRNewswire Asia

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite...

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

by | PRNewswire Asia

HONG KONG, Dec. 7, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company’s self-developed innovative drugs into the updated National Reimbursement Drug List...

SURFIRAN CO LTD Leads a New Gourmet Category in Korea with Premium Saffron Products

by | PRNewswire Asia

SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ — SURFIRAN CO LTD is emerging as a pioneer in Korea’s gourmet food market by introducing saffron-based products and raising awareness of saffron—one of the world’s top three gourmet treasures alongside...